Or rephrased, has HLA-G an active, functional role in tumour progression which leads to poor clinical patient outcome or is HLA-G expression a by-product of an increased genomic instability in the tumours of patients with poor clinical outcome? This evidence concerns the gene HLA-G and neoplasm.